Novel therapeutic approach to primary biliary cirrhosis patients

Anti-eosinophil strategy

Shingo Miyaguchi, Masaya Oda, Hidetsugu Saito, Hiromasa Ishii

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Primacy biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown cause. Morphologically, PBC is characterized by eosinophil infiltration into the portal tract in recent studies. Pranlukast, a new drug, is a leukotriene antagonist, which suppresses eosinophil infiltration in atopic dermatitis or asthma. METHODOLOGY: In this study, pranlukast monotherapy was used to treat 12 patients with a diagnosis of PBC, classified as stage I or II according to Scheuer's classification on the basis of liver biopsy findings. RESULTS: An improvement in alkaline phosphatase (ALP) was observed beginning one month after the start of pranlukast therapy in all 12 patients. Improvement in ALP and y-GTP values was stastically observed at 1, 2, and 6 months after the start of treatment. IgG and IgM values improved in all 12 patients at 2 months and 6 months after the start of treatment. Absolute eosinophil counts improved at 6 months after the start of treatment. CONCLUSIONS: Given its efficacy and the absence of side effects, planlukast appears to be the medical treatment of choice for patients with early-stage PBC. But, a randomised, controlled, double-blind trial is urgently needed.

Original languageEnglish
Pages (from-to)1457-1461
Number of pages5
JournalHepato-Gastroenterology
Volume45
Issue number23
Publication statusPublished - 1998

Fingerprint

Biliary Liver Cirrhosis
Eosinophils
Alkaline Phosphatase
Leukotriene Antagonists
Therapeutics
Atopic Dermatitis
Guanosine Triphosphate
Immunoglobulin M
Liver Diseases
Asthma
Immunoglobulin G
Biopsy
Liver
Pharmaceutical Preparations
pranlukast

Keywords

  • Eosinophils
  • Pranlukast
  • Primary biliary cirrhosis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Novel therapeutic approach to primary biliary cirrhosis patients : Anti-eosinophil strategy. / Miyaguchi, Shingo; Oda, Masaya; Saito, Hidetsugu; Ishii, Hiromasa.

In: Hepato-Gastroenterology, Vol. 45, No. 23, 1998, p. 1457-1461.

Research output: Contribution to journalArticle

Miyaguchi, Shingo ; Oda, Masaya ; Saito, Hidetsugu ; Ishii, Hiromasa. / Novel therapeutic approach to primary biliary cirrhosis patients : Anti-eosinophil strategy. In: Hepato-Gastroenterology. 1998 ; Vol. 45, No. 23. pp. 1457-1461.
@article{9edb3a94cddd44978baad6b0397843a5,
title = "Novel therapeutic approach to primary biliary cirrhosis patients: Anti-eosinophil strategy",
abstract = "BACKGROUND/AIMS: Primacy biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown cause. Morphologically, PBC is characterized by eosinophil infiltration into the portal tract in recent studies. Pranlukast, a new drug, is a leukotriene antagonist, which suppresses eosinophil infiltration in atopic dermatitis or asthma. METHODOLOGY: In this study, pranlukast monotherapy was used to treat 12 patients with a diagnosis of PBC, classified as stage I or II according to Scheuer's classification on the basis of liver biopsy findings. RESULTS: An improvement in alkaline phosphatase (ALP) was observed beginning one month after the start of pranlukast therapy in all 12 patients. Improvement in ALP and y-GTP values was stastically observed at 1, 2, and 6 months after the start of treatment. IgG and IgM values improved in all 12 patients at 2 months and 6 months after the start of treatment. Absolute eosinophil counts improved at 6 months after the start of treatment. CONCLUSIONS: Given its efficacy and the absence of side effects, planlukast appears to be the medical treatment of choice for patients with early-stage PBC. But, a randomised, controlled, double-blind trial is urgently needed.",
keywords = "Eosinophils, Pranlukast, Primary biliary cirrhosis",
author = "Shingo Miyaguchi and Masaya Oda and Hidetsugu Saito and Hiromasa Ishii",
year = "1998",
language = "English",
volume = "45",
pages = "1457--1461",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "23",

}

TY - JOUR

T1 - Novel therapeutic approach to primary biliary cirrhosis patients

T2 - Anti-eosinophil strategy

AU - Miyaguchi, Shingo

AU - Oda, Masaya

AU - Saito, Hidetsugu

AU - Ishii, Hiromasa

PY - 1998

Y1 - 1998

N2 - BACKGROUND/AIMS: Primacy biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown cause. Morphologically, PBC is characterized by eosinophil infiltration into the portal tract in recent studies. Pranlukast, a new drug, is a leukotriene antagonist, which suppresses eosinophil infiltration in atopic dermatitis or asthma. METHODOLOGY: In this study, pranlukast monotherapy was used to treat 12 patients with a diagnosis of PBC, classified as stage I or II according to Scheuer's classification on the basis of liver biopsy findings. RESULTS: An improvement in alkaline phosphatase (ALP) was observed beginning one month after the start of pranlukast therapy in all 12 patients. Improvement in ALP and y-GTP values was stastically observed at 1, 2, and 6 months after the start of treatment. IgG and IgM values improved in all 12 patients at 2 months and 6 months after the start of treatment. Absolute eosinophil counts improved at 6 months after the start of treatment. CONCLUSIONS: Given its efficacy and the absence of side effects, planlukast appears to be the medical treatment of choice for patients with early-stage PBC. But, a randomised, controlled, double-blind trial is urgently needed.

AB - BACKGROUND/AIMS: Primacy biliary cirrhosis (PBC) is a chronic cholestatic liver disease of unknown cause. Morphologically, PBC is characterized by eosinophil infiltration into the portal tract in recent studies. Pranlukast, a new drug, is a leukotriene antagonist, which suppresses eosinophil infiltration in atopic dermatitis or asthma. METHODOLOGY: In this study, pranlukast monotherapy was used to treat 12 patients with a diagnosis of PBC, classified as stage I or II according to Scheuer's classification on the basis of liver biopsy findings. RESULTS: An improvement in alkaline phosphatase (ALP) was observed beginning one month after the start of pranlukast therapy in all 12 patients. Improvement in ALP and y-GTP values was stastically observed at 1, 2, and 6 months after the start of treatment. IgG and IgM values improved in all 12 patients at 2 months and 6 months after the start of treatment. Absolute eosinophil counts improved at 6 months after the start of treatment. CONCLUSIONS: Given its efficacy and the absence of side effects, planlukast appears to be the medical treatment of choice for patients with early-stage PBC. But, a randomised, controlled, double-blind trial is urgently needed.

KW - Eosinophils

KW - Pranlukast

KW - Primary biliary cirrhosis

UR - http://www.scopus.com/inward/record.url?scp=0031794312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031794312&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 1457

EP - 1461

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 23

ER -